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1. Introduction 
Infections of prosthetic grafts in vascular surgery are the cause of many serious 
postoperative complications including death (Bahnini et al.,1991; Callow,1996; Wilson,2001; 
Yeager&Porter,1992). Encouraging results were obtained when cold-preserved fresh arterial 
homografts and other biologic grafts were used to replace infected prosthetic grafts (Chiesa 
et al.,1998, 2002). Cooling down the grafts only to 4OC allows preservation of the arterial 
endothelium. However, the endothelium is immunogenic, and thus immunosuppression is 
needed (Cerilli et al.,1985; Methe et al.,2007; Paul et al.,1985; Pober et al.,1984). Moreover, 
organ donors should be selected with respect to histocompatibility and blood group types 
(Gabriel et al.,2002; Mirelli et al.,1998, 1999; Scolari et al.,1998). Experimental studies show 
that immunosuppressive treatment is helpful after the implantation of cold-preserved fresh 
arterial homografts (Azuma et al.,1999; Gabriel&Fandrich,2002). On the other hand, there is 
a concern that immunosuppressive drugs can exacerbate the infection. There are no clinical 
studies examining the need to use immunosuppression after the transplantation of fresh 
arterial homografts in prosthetic graft infections (Mirelli et al.,1999). We assumed that 
administration of Cyclosporine A with a concomitant antibiotic therapy may improve the 
viability of the fresh arterial homografts and improve the patients’ condition. 
One of the diagnostic methods used to detect infections in vascular surgery is scintigraphy 
with the use of Technetium-99m labeled leucocytes. Leucocytes migrate and accumulate in 
the infected area allowing for the area of accumulation to be estimated (Plissonnier et 
al.,1995). Objective monitoring of the infection after an arterial graft implantation facilitates 
the decision of choosing the right treatment, especially for patients treated with 
immunosuppressive drugs.    
The aim of our study was to assess the influence of Cyclosporine A administration on the 
outcome of patients who underwent fresh arterial homograft transplantation in the 
treatment of prosthetic graft infections. 
2. Materials and methods  
2.1 Study design 
We carried out a prospective, non-randomized observational study. 79 patients were 
admitted to our clinic between March 2001 and January 2009 due to a prosthetic graft 
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infection. In all cases we observed infection of the prosthetic graft with purulent fistulas, 
fluid spaces around the prostheses and bleeding from the vascular anastomoses. All patients 
that could not wait for the fresh arterial homograft had the prosthesis replaced with a silver 
coated prosthesis (27 patients). 52 patients who could wait for the arterial homograft were 
put on a waiting list and were treated with antibiotics and local disinfectants until they had 
the infected prosthesis replaced with an arterial homograft. According to the protocol 
approved by the Ethics Committee of the University of Medicine of Wroclaw, patients 
decided whether they wanted to take Cyclosporine A after obtaining detailed information 
about the possible benefits and risks of taking this medication.   We defined early and late 
postoperative periods as ≤30 days and >30days respectively. The patients were divided into 
2 groups: Group 1 – consisting of 26 patients who received 1-3 mg/kg of Cyclosporine A per 
day with dose adjustments to maintain a serum concentration of 120-140 mg/ml and group 
2 - consisting of 26 patients who were treated without immunosuppressive drugs (Table 1). 
All patients with positive cross-match were assigned to group 1 (3 patients). 
 
Characteristics of homograft recipients Group 1 (N=26) Group 2 (N=26) 
Age (years, mean+-SD) 42-68 (57±1) 50-71 (59±5) 
Male 25 24 
Female 1 2 
Additional illnesses  
Diabetes 8 (30%) 8 (31%) 
Ischemic heart disease 15 (58%) 14 (54%) 
Renal failure 4 (15%) 4 (15%) 
Leg necrosis 7 (27%) 6 (23%) 
Graft-duodenal fistula 6 (23%) 5 (19%) 
Table 1. Characteristics of homografts recipients 
In each case, the infection was confirmed with Duplex- Doppler Ultrasound, CT and 
scintigpraphy using Technetium-99m labeled leucocytes. The patients received antibiotics 
(vancomycin, ciprofloxacin, imipenem) according to the antibiogram, usually for a period of 
up to 30 days after the operation.  
All of the homografts were evaluated before the implantation using scanning electron 
microscopy. In each case, the examination revealed a non-damaged arterial wall and the 
presence of the endothelium. 
 
Immunological characteristics of patients qualified for an arterial transplantation 
Homograft Group 1 (N=26) Group 2 (N=26) 
ABO compatibility 
Negative cross-match 
Number of incompatibilities in HLA (average+-SD)
Negative virological examination in donor 
Time of graft’s preservation (hrs, average+-SD) 
26 (100%) 
23 (88%) 
3.7±1.8 
26 (100%) 
6-24 (15.2±4.8) 
26 (100%) 
26 (100%) 
3.7±1.5 
26 (100%) 
8-22 (14.4±4.9) 
Table 2. Immunological characteristics of patients qualified for an arterial transplantation 
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2.2 Patients 
2.2.1 Group 1 
The administration of Cyclosporine A (Sandimmun®; Novartis Pharma GmbH) began 
intraoperatively after revascularization. In this group, 21 Y-shaped, 4 ilio-femoral and 1 
aorto-femoral cold-preserved fresh arterial grafts were implanted. The time of simple 
hypothermia preservation of aortic allografts did not exceed 24 hours.  3 patients from this 
group had slightly positive cross-match results with the donors' lymphocytes. 
Microbiological cultures from the specimens from the groin, retroperitoneal space and the 
infected prosthesis revealed MRSA (24 patients; 92 %), Staphylococcus epidermidis (10; 38%) 
and Pseudomonas aeruginosa (7; 27%) infections.  
2.2.2 Group 2 
In group 2, 22 bifurcated and 4 ilio-femoral arterial allografts were implanted. The time of 
homograft preservation did not exceed 22 hours. Bacteriological cultures confirmed the 
infection with MRSA (21 patients; 81%), S.epidermidis (9; 35%) and P.aeruginosa (5; 19%).  
2.3 Homografts 
There was no statistical difference in tissue histocompatibility between both groups (Table 
2). Arterial homografts were collected from dead donors with a confirmed brain death. 
During this procedure, a fragment of an artery was taken for a microbiological and 
microscopic evaluation. Homografts were preserved in the UW (University of Wisconsin) 
fluid. Just before the operation, the tissues surrounding the allograft were removed and 
smaller arterial branches were tied up using monofilament sutures.  
2.4 Methods 
The postoperative treatment (the course of infection and the effects of the therapy), was 
monitored using scintigraphy. Before and after the operation, computed tomography (CT), 
duplex-doppler ultrasound, and in some cases, angiography were performed. 
Microbiological examination, tissue histocompatibility (A and B locus from class I HLA and 
D locus from class II HLA), ABO compatibility and cross-matches were carried out in 
every patient. The activity of CD3+, CD4+ and CD8+ lymphocytes was measured before 
and after the vascular procedure on the 1st, 3rd, 7th day, and in the 1st, 3rd, 6th, 12th, 
18th and 24th month after the operation. Virological and serological examinations were 
performed in each donor (anty-HIV, HBs-Ag, anty-HBc, anty-HCV, anty-EBV, Hbe-Ag, 
anty-CMV, VDRL test). 
The primary endpoint was the recurrence of infection confirmed by clinical and laboratory 
examinations or by scintigraphy. Secondary endpoints were early and late postoperative 
mortality and morbidity, amputations, graft patency, rupture of the graft and presence of 
the graft aneurysm. 
2.5 Statistical analysis 
Statistical analysis was performed with the use of Statistica 9,0 software. The results were 
analyzed by parametrical and non-parametrical tests such as chi-square, chi-square analysis 
of variance (ANOVA) and the U test of Mann-Whitney. Statistical significance was assumed 
at p<0.05. 
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2.6 Ethical approval for research 
The protocol of this study was approved by the Ethics Committee of the University of 
Medicine of Wroclaw. 
3. Results  
52 patients were enrolled into the study. The mean ± standard deviation (SD) follow-up was 
23.3 ± 6.1 months in group 1 and 19.2 ± 10.7 months in group 2. A long-term follow up was 
completed for 15 patients from group 1 and 14 from group 2. 
3.1 Postoperative morbidity and mortality 
3.1.1 Postoperative mortality 
In group 1, one (4%) patient with an aorto-duodenal fistula died 14 days after the operation 
due to septic shock and one (4%) died 11 months after the operation due to a 
cerebrovascular accident. In group 2, four (15%) patients died in the early postoperative 
period. Two patients (8%) died due to a graft-duodenal fistula on the 5th and 19th 
postoperative day, one (4%) in the course of septic shock (3rd day) and one (4%) due to 
myocardial infarction (7th day).  Two (8%) patients died in the late postoperative period due 
to rupture of the allograft (4th and 5th postoperative month) (Table 3, Fig.1). The mortality 
was higher in group 2 (23%) than in group 1 (8%), but this difference failed to reach 
statistical significance (p>0.05).  
 
Postoperative mortality 
Group 1  
(N=26) 
Group 2  
(N=26) 
Early<30 days 
Septic shock 1 (4%) 1 (4%) 
Graft-duodenal fistula - 2 (8%) 
Myocardial infarction - 1 (4%) 
 1 (4%) 4 (15%) 
Late>30 days 
Rupture of graft - 2 (8%) 
Cerebrovascular accident 1 (4%) - 
 1 (4%) 2 (8%) 
Table 3. Postoperative mortality 
3.1.2 Postoperative morbidity 
In the group treated with cyclosporine, three (12%) early complications (graft thrombosis, 
wound dehiscene with evisceration, a hematoma in the inquinal area) and three (12%) late 
complications (symptoms of bowel ischemia, lower extremity ischemia, tibial arteries 
occlusion) were observed. Graft aneurysms or late thrombosis of the transplanted artery 
were not detected in this group. In the group treated without immunosuppression, there 
were no early complications and 9 (35%) late complications (MRSA inferction of the 
homograft, 5 cases of homograft aneurysms of which 3 ruptured and 3 femoral amputations 
due to graft thrombosis) (Table 4).  The incidence of late postoperative complications was 
statistically greater in group 2 than in group 1 (p=0.030). There was no statistically 
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significant difference between group 1 and 2 in the occurrence of early postoperative 
complications and in the number of both early and late complications.  
 
 
Fig. 1. Kapalan-Meier survival analysis of the patients 
 
Postoperative morbidity 
Group 1 
(N=26) 
Group 2 
(N=26) 
Early<30 days 
Infection of postoperative wound 1 (4%) - 
Graft thrombosis 1 (4%) - 
Hematoma 1 (4%) - 
 3 (12%) 0 (0%) 
Late>30 days 
Graft infection - 1 (4%) 
Graft thrombosis - amputation - 3 (12%) 
Low extremity ischemia 2 (8%) - 
Graft aneurysm - 2 (8%) 
Symptoms of bowel ischemia 1 (4%) - 
Rupture of graft - 3 (12%) 
 3 (12%) 9 (35%) 
Table 4. Postoperative morbidity 
3.2 Laboratory and radiological examinations 
In both groups, laboratory and radiological examinations confirmed the regression of the 
infection after the arterial graft implantation. Acute phase proteins were within normal 
range. The ultrasound examination showed no evidence of fluid spaces around the 
homografts. Scintigraphy revealed the statistically significant (p=0.011) decrease of 
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accumulation of the Tc-99m labeled leucocytes around the allograft in both groups during 
the whole observation period of 27 months. The biggest drop in the area of accumulated 
leucocytes was in the 6th postoperative month in both groups. The rate of the decrease was 
slightly greater in the group without immunosuppression, but this difference did not reach 
statistical significance. 
 
 
Fig. 2. The reduction of the area of accumulation of Tc99-labelled lymphocytes in patients 
from group 1 (with Cyclosporine A) 
 
 
Fig. 3. The reduction of the area of accumulation of Tc99-labelled lymphocytes in patients 
from group 2 (without Cyclosporine A) 
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The total reduction of the area of accumulation of the Tc-99m labeled leucocytes during the 
postoperative period was 35% in group 1 and 44% in group 2 (Fig. 2,3). The statistically 
significant (p=0.016) difference between both groups in the area of accumulation was 
observed 18 months after the operation, and it was bigger in group 2.   
When there was an increase or no decrease of the leucocytes accumulation, antibiotics were 
administered according to the antibiogram.  This took place 4 times in group 1 (15%) and 3 
times in group 2 (12%). The antibacterial treatment resulted in the reduction of the 
leucocytes accumulation and there were no further clinical signs of reinfection. 
3.3 The activity of CD3+, CD4+ and CD8+ lymphocytes in blood 
The analysis of the immunological response in both examined groups revealed an increase 
in the activity of CD3+ and CD4+ lymphocytes and a decrease in the activity of CD8+ 
lymphocytes. The increase in activity of CD3+ lymphocytes in group 1 was observed from 
the first postoperative day and it was statistically significant (p=0.04). The increase in 
activity of CD3+ lymphocytes was greater in group 2 than in group 1, and reached its 
maximal value on the 7th postoperative day (Fig.4,5). This difference in activity was also 
statistically significant (p=0.038). Statistical differences in CD3+ lymphocyte activity 
between both groups began in the sixth postoperative month and lasted until the 24th 
month (p=0.027).  
 
 
Fig. 4. The CD3+ lymphocytes’ activity in patients from group 1 (with Cyclosporine) 
The increase in activity of CD4+ lymphocytes was larger in group 2 than in group 1 (Fig. 
6,7). The change in activity of CD4+ lymphocytes in both groups was statistically 
significant (p=0.035). The maximum activity was noted on the 7th postoperative day. A 
statistically significant difference in activity of CD4+ lymphocytes between both groups 
was seen on the first day (p=0.032) and in the third month after the arterial graft 
implantation (p=0.041).  
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Fig. 5. The CD3+ lymphocytes’ activity in patients from group 2 (without Cyclosporine) 
 
 
Fig. 6. The CD4+ lymphocytes’ activity in patients from group 1 (with Cyclosporine) 
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Fig. 7. The CD4+ lymphocytes’ activity in patients from group 2 (without Cyclosporine) 
The decrease in activity of CD8+ lymphocytes was at its maximum on the 7th day in group 1 
and in the 1st month in group 2 after the operation (Fig. 8,9). This decrease was statistically 
significant (p=0.02) in both examined groups. The difference in activity of these leucocytes 
between group 1 and 2 was statistically significant (p=0.016) in the 18th month of the 
observation and was greater in group 2.  
 
 
Fig. 8. The CD8+ lymphocytes’ activity in patients from group 1 (with Cyclosporine) 
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Fig. 9. The CD8+ lymphocytes’ activity in patients from group 2 (without Cyclosporine) 
3.4 Scanning electron microscopy 
Scanning electron microscopy examinations were performed in two patients. One patient 
from group 1 and another one from group 2 had the arterial homografts removed due to late 
postoperative complications. The tissue specimens were prepared in the usual manner and 
assessed by an experienced histologist.  
9 months after the transplantation, we collected a fragment of the ilio-femoral homograft 
from a patient from group 2, who had the transplanted artery removed due to an MRSA 
infection and rupture of the graft. Scanning electron microscopy (SEM) revealed a complete 
destruction of the homograft's wall - absence of the endothelium, single, damaged cells and 
cell fragments of the medial membrane (Fig.11). 
We collected a fragment of the artery from a patient from group 1, who was operated on 13 
months after the homograft implantation due to an arterial embolism.  SEM showed the 
presence of the endothelial cells (which were mechanically detached), the intimal wall with 
thickened elastic lamina, a large amount of elastic and collagen fibres, fibrin inclusions, 
active myoblasts and myofibroblasts (Fig.10). The above mentioned patient stopped taking 
prescribed immunosuppressive drugs and was admitted to the hospital 12 months after the 
previous embolectomy. He suffered from lower extremity ischemia in the course of an 
arterial homograft embolism. Thrombectomy was carried out but this procedure did not 
improve the blood supply to the leg. Consequently, an amputation was performed. During 
this operation, a fragment of the arterial homograft's wall was collected. SEM revealed the 
absence of endothelial cells and the presence of cell apoptosis.  
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Fig. 10. Scanning electron microscope image - homograft with immunosuppression. A) 
Endothelial cells. B) Thickened elastic lamina of the intimal wall. C) Active myofibroblasts 
fagocyting lipids. D) Active myofibroblasts producing collagen 
 
 
 
Fig. 11. Scanning electron microscope image - homograft without immunosuppression. 
 A) Absence of endothelium. B) Apoptosis 
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4. Discussion 
The infections of synthetic prostheses in our study were classified as third degree, according 
to the Szilagy scale, and fifth degree according to the Samson scale (Samson et al.,1988; 
Szilagyi et al.,1972). The replacement of the infected prosthesis with an arterial allograft was 
a reasonable solution in these life threatening conditions. We chose cold-preserved fresh 
arterial homografts because we believed the deep-freeze method was more likely to 
decrease long-term viability of the arterial wall and less likely to cause the degradation of 
the endothelium (Bujan et al.,2000; Desgranges et al.,1998; Manaa et al.,2003; Pascual et 
al.,2001, 2002; Vischjager et al., 1996a, 1996b).  
Some  scientists   claim that the arterial   homograft  is characterized  by  low immunogenity  
and maintain that the graft rejection  process is  inconsiderable and does not cause  an  
impaired functioning and survivability of the graft (Mirelli et al.,1998, 1999). This is why 
some vascular surgery centers transplant the arteries without the selection of ABO and HLA 
compatible donors. There are also numerous research studies showing that the usage of 
fresh arterial homografts with a preserved endothelium is associated with the 
immunological response of the graft recipient. This suggests the importance of the selection 
of donors of the same blood type and similar HLA histocompatibility when fresh arterial 
allografts are to be used (Chiesa et al.,1998; da Gama et al.,1994; Mirelli et al.,1998, 1999; 
Prager et al.,2002). We believe that in life threatening infections, the transplantation of the 
artery despite a slightly positive cross-match is acceptable. In this situation, the usage of 
immunosuppressive drugs is reasonable. However, we agree that the ABO compatibility is 
essential (Bracale et al.,1999; Chiesa et al.,1998; Prager et al.,2002).   
Clinical trials show that there are changes in an arterial homograft's wall typical for a 
chronic rejection process (Allaire et al.,1994; Bandyk et al.,2001; Mirelli et al.,1999; Ruotolo et 
al.,1997). Immunosuppressive treatment can help to stop the degradation of the arterial wall 
and prolong its viability (Vischjager et al.,1996a, 1996b). However, there is still a question of 
whether or not to use these drugs in the presence of the infection.    
Prolonged functioning of the arterial graft in patients treated with the immunosuppressive 
drugs was confirmed in some experimental trails (Deaton et al.,1992; Miller et al.,1993; 
Vermassen et al.,1991; Vischjager et al.,1996). In his experimental trial, Azuma et al. 
observed that lack or discontinuation of the intake of immunosuppressive medications 
caused the degradation of the arterial graft’s wall and loss of the endothelial cells (Azuma et 
al.,1999). It was also proven that insufficient dosages of these drugs caused an impaired 
functioning of the transplanted artery (Gabriel et al.,2002; Geerling et al.,1994; Stoltenberg et 
al.,1995).  
In our study, the increase in activity of CD3+ and CD4+ lymphocytes and the decrease in 
activity of CD8+ lymphocytes (probably caused by the increase of the infiltration of the 
homograft's wall by these cells) in transplanted patients suggest arterial allograft's 
antigenicity.A larger decrease in CD3+ and CD4+ lymphocyte activity and a smaller 
decrease in CD8+ lymphocyte activity were observed in patients treated with Cyclosporine 
A than in those treated without immunosuppression. We assume that this was caused by 
the reduced immunological response of T helper lymphocytes (CD4+) and a smaller 
infiltration of the allograft by cytotoxic lymphocytes (CD8+). We also believe that this 
mechanism could help to keep the arterial wall undamaged (Mirelli et al.,1998, 1999).  
One month of an antibiotic therapy and the replacement of the infected prosthesis with an 
arterial homograft lead to the remission of the infection despite the immunosuppressive 
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treatment in almost all patients. This was confirmed with radiological examinations, mainly 
scintigraphy, using Technetium-99m labeled leucocytes. The maintenance of a small 
accumulation of the labeled leucocytes around the homograft can be regarded as a chronic 
reaction against the foreign tissue. We stopped administering the antibiotics according to 
the scintigraphy results. Prolonged antibiotic and cyclosporine A therapy did not cause any 
complications associated with decreased immunity. We assume that the application of 
immunosuppressive drugs reduced the immunological response of the patients against 
transplanted grafts.  
In patients who received immunosuppressive drugs no graft aneurysms were observed 
compared to 5 cases (19%) of this complication in patients without this therapy. 
Cyclosporine A may have helped to stop the degradation process of the arterial wall and 
thus prevented its aneurismal dilatation. The number of cases of postoperative infections 
was even smaller in those who received immunosuppressive medications. Our study 
suggests that profits from reasonable immunosuppression outweigh the risk of potential 
infection in patients with an arterial homograft implanted due to infection of a vascular 
prosthesis.  
5. Conclusions 
We believe that Cyclosporine A helped to stop the processes of damaging the graft's wall. 
Patients treated with this drug had fewer late postoperative complications. Our study 
suggests that cyclosporine A can be used in patients with an infection of a synthetic vascular 
prosthesis, undergoing the implantation of a fresh arterial allograft. We found out that fresh 
arterial homografts may be immunogenic in an extent which leads to its chronic rejection by 
the patient’s immunological system. The results support the hypothesis that Cyclosporine A 
may prevent the autoimmunologic response of the patient and reduce the risk of damaging 
the arterial homograft. 
 Our study was carried out on a relatively small group of patients and it could be the reason 
why some of the differences between both examined groups of patients failed to reach 
statistical significance. Therefore, a multicentre randomized trial is needed to definitively 
establish the role of immunosuppression in the treatment of prosthetic vascular graft 
infections with the use of arterial homografts. 
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